{"title":"伊朗的巩膜炎。","authors":"Sahba Fekri, Reza Esmaili Fallah, Masoud Soheilian, Seyed-Hossein Abtahi, Hosein Nouri","doi":"10.1186/s12348-025-00473-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To present the demographic and clinical presentations of anterior scleritis among Iranian patients.</p><p><strong>Methods: </strong>This retrospective case-series at a tertiary center in Iran, identified and analyzed anterior scleritis cases admitted from 2008 to 2018. Extracted data included demographics, clinical features, background systemic diseases, utilized therapies, and follow-up data on visual outcomes, ocular complications, and recurrence rate. Patients with incomplete records were excluded from the analysis.</p><p><strong>Results: </strong>Sixty-five patients (83 eyes) with anterior scleritis were included, with a female predilection (77%) and a mean age (± SD; range) of 44.8 (± 14.6; 11-81). Diffuse and necrotizing scleritis were the most and least common subtypes, respectively. Bilateral involvement (28% at baseline, 44.6% eventually) and concurrent keratitis (10.7%) or uveitis (16.9%) were documented in some cases. Most cases were idiopathic (61.5%). Scleritis was the initial manifestation of autoimmune diseases in six patients. In addition to oral and/or intravenous corticosteroid therapy, most of our patients (70.7%) were treated with immunosuppressive regimens. No inter-subtype difference was noted in recurrence rate and time to treatment cessation. Necrotizing subtype was associated with worse visual outcomes and more frequent ocular complications.</p><p><strong>Conclusion: </strong>Despite limitations in data collection and follow-up, our findings contribute valuable insights into the clinical characteristics and management of scleritis in a group of Iranian patients for the first time.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"15 1","pages":"17"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880481/pdf/","citationCount":"0","resultStr":"{\"title\":\"Scleritis in Iran.\",\"authors\":\"Sahba Fekri, Reza Esmaili Fallah, Masoud Soheilian, Seyed-Hossein Abtahi, Hosein Nouri\",\"doi\":\"10.1186/s12348-025-00473-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To present the demographic and clinical presentations of anterior scleritis among Iranian patients.</p><p><strong>Methods: </strong>This retrospective case-series at a tertiary center in Iran, identified and analyzed anterior scleritis cases admitted from 2008 to 2018. Extracted data included demographics, clinical features, background systemic diseases, utilized therapies, and follow-up data on visual outcomes, ocular complications, and recurrence rate. Patients with incomplete records were excluded from the analysis.</p><p><strong>Results: </strong>Sixty-five patients (83 eyes) with anterior scleritis were included, with a female predilection (77%) and a mean age (± SD; range) of 44.8 (± 14.6; 11-81). Diffuse and necrotizing scleritis were the most and least common subtypes, respectively. Bilateral involvement (28% at baseline, 44.6% eventually) and concurrent keratitis (10.7%) or uveitis (16.9%) were documented in some cases. Most cases were idiopathic (61.5%). Scleritis was the initial manifestation of autoimmune diseases in six patients. In addition to oral and/or intravenous corticosteroid therapy, most of our patients (70.7%) were treated with immunosuppressive regimens. No inter-subtype difference was noted in recurrence rate and time to treatment cessation. Necrotizing subtype was associated with worse visual outcomes and more frequent ocular complications.</p><p><strong>Conclusion: </strong>Despite limitations in data collection and follow-up, our findings contribute valuable insights into the clinical characteristics and management of scleritis in a group of Iranian patients for the first time.</p>\",\"PeriodicalId\":16600,\"journal\":{\"name\":\"Journal of Ophthalmic Inflammation and Infection\",\"volume\":\"15 1\",\"pages\":\"17\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11880481/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ophthalmic Inflammation and Infection\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12348-025-00473-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ophthalmic Inflammation and Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12348-025-00473-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Purpose: To present the demographic and clinical presentations of anterior scleritis among Iranian patients.
Methods: This retrospective case-series at a tertiary center in Iran, identified and analyzed anterior scleritis cases admitted from 2008 to 2018. Extracted data included demographics, clinical features, background systemic diseases, utilized therapies, and follow-up data on visual outcomes, ocular complications, and recurrence rate. Patients with incomplete records were excluded from the analysis.
Results: Sixty-five patients (83 eyes) with anterior scleritis were included, with a female predilection (77%) and a mean age (± SD; range) of 44.8 (± 14.6; 11-81). Diffuse and necrotizing scleritis were the most and least common subtypes, respectively. Bilateral involvement (28% at baseline, 44.6% eventually) and concurrent keratitis (10.7%) or uveitis (16.9%) were documented in some cases. Most cases were idiopathic (61.5%). Scleritis was the initial manifestation of autoimmune diseases in six patients. In addition to oral and/or intravenous corticosteroid therapy, most of our patients (70.7%) were treated with immunosuppressive regimens. No inter-subtype difference was noted in recurrence rate and time to treatment cessation. Necrotizing subtype was associated with worse visual outcomes and more frequent ocular complications.
Conclusion: Despite limitations in data collection and follow-up, our findings contribute valuable insights into the clinical characteristics and management of scleritis in a group of Iranian patients for the first time.